@JosephineDeBeauharnais
Thank you - so far, so good.
Perhaps an element of closer scrutiny is numbers in the trial now that so many people have dropped out?
I’m not sure that this matters because they had sufficient people in for long enough to achieve statistical significance in their primary endpoint, which should be good enough for the regulatory authorities. The paper from this study is just about ready to be submitted to the New England Journal of Medicine, so will hopefully be available to read online in a few weeks.
Frazzled is right about the numbers scaling up - the nasty blood clots with AZ are seen in something like 1 in 250,000 people. As Novavax has been given to far fewer people (I’m not sure how many are in the US trial, but I think it’s a similar size to ours) the chances of seeing one are very low at the moment. (There haven’t been any
)